A detailed history of O'Shaughnessy Asset Management, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, O'Shaughnessy Asset Management, LLC holds 3,729 shares of ALNY stock, worth $878,403. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,729
Previous 993 275.53%
Holding current value
$878,403
Previous $241,000 325.31%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$233.81 - $287.01 $639,704 - $785,259
2,736 Added 275.53%
3,729 $1.03 Million
Q2 2024

Aug 14, 2024

SELL
$143.31 - $247.0 $170,252 - $293,436
-1,188 Reduced 54.47%
993 $241,000
Q1 2024

May 13, 2024

BUY
$146.51 - $198.2 $27,983 - $37,856
191 Added 9.6%
2,181 $325,000
Q4 2023

Feb 09, 2024

BUY
$151.41 - $196.57 $59,958 - $77,841
396 Added 24.84%
1,990 $380,000
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $44,058 - $54,605
258 Added 19.31%
1,594 $282,000
Q2 2023

Aug 11, 2023

BUY
$185.01 - $212.05 $247,173 - $283,298
1,336 New
1,336 $253,000
Q4 2022

Feb 10, 2023

BUY
$185.53 - $241.31 $187,014 - $243,240
1,008 New
1,008 $239,000
Q4 2021

Feb 11, 2022

SELL
$159.56 - $209.29 $35,103 - $46,043
-220 Closed
0 $0
Q3 2021

Nov 10, 2021

BUY
$169.75 - $207.73 $15,617 - $19,111
92 Added 71.88%
220 $42,000
Q4 2020

Feb 11, 2021

SELL
$122.97 - $147.0 $245 - $294
-2 Reduced 1.54%
128 $17,000
Q3 2020

Nov 12, 2020

SELL
$121.19 - $165.49 $969 - $1,323
-8 Reduced 5.8%
130 $19,000
Q2 2020

Aug 13, 2020

BUY
$104.21 - $156.44 $12,192 - $18,303
117 Added 557.14%
138 $20,000
Q1 2020

May 13, 2020

BUY
$93.12 - $133.99 $1,024 - $1,473
11 Added 110.0%
21 $2,000
Q4 2019

Feb 12, 2020

BUY
$74.51 - $124.23 $745 - $1,242
10 New
10 $1,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track O'Shaughnessy Asset Management, LLC Portfolio

Follow O'Shaughnessy Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Shaughnessy Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on O'Shaughnessy Asset Management, LLC with notifications on news.